Patient experiences and preferences for IV versus subcutaneous immunotherapy in non-small cell lung cancer
Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study
This survey asks people with non-small cell lung cancer who are receiving immune checkpoint inhibitors whether they prefer IV treatment or subcutaneous injections at the hospital or at home.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Southern California Academic / other |
| Drugs / interventions | Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, chemotherapy, immunotherapy |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Trial ID | NCT07339254 on ClinicalTrials.gov |
What this trial studies
This single-center observational survey enrolls adult patients with confirmed non-small cell lung cancer who have already received at least one cycle of an immune checkpoint inhibitor (atezolizumab, cemiplimab, durvalumab, nivolumab, or pembrolizumab). Participants complete questionnaires about satisfaction with IV infusions, perceived safety, convenience, and comfort, and about their preference for IV versus subcutaneous (SC) administration and location (hospital vs home). No experimental treatments are given; the study only collects patient-reported experiences and preferences. Results will be used to inform care delivery options and patient-centered administration strategies.
Who should consider this trial
Good fit: Adults (≥18) with histologically or cytologically confirmed non-small cell lung cancer who have received at least one cycle of an eligible immune checkpoint inhibitor and can provide informed consent.
Not a fit: Patients who have not yet started immune checkpoint inhibitors, who cannot consent, or who receive therapies other than the listed ICIs are unlikely to benefit from participation.
Why it matters
Potential benefit: If findings show clear patient preferences, clinics could change how immunotherapy is delivered to improve comfort, convenience, and satisfaction.
How similar studies have performed: Previous patient surveys in oncology have captured infusion versus injection preferences, but data specifically comparing IV immune checkpoint inhibitors to home subcutaneous delivery are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \* Age ≥ 18 years. * \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy) * \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint. * \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent. Exclusion Criteria: * \* Patients is unable to consent for themselves * \* Patient has not yet completed the 1st cycle of ICI-based therapy
Where this trial is running
Los Angeles, California and 1 other locations
- Los Angeles General Medical Center — Los Angeles, California, United States (Recruiting)
- USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Robert Hsu — University of Southern California
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.